Rebecca C. Furze

Stevenage, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Pulmonary monocyte kinetics in healthy volunteers and subjects with inflammatory arthritis.

Pulmonary monocyte kinetics in healthy volunteers and subjects with inflammatory arthritis.

Journal: Thorax

Published: June 29, 2026

A BET Protein Inhibitor Targeting Mononuclear Myeloid Cells Affects Specific Inflammatory Mediators and Pathways in Crohn's Disease.

A BET Protein Inhibitor Targeting Mononuclear Myeloid Cells Affects Specific Inflammatory Mediators and Pathways in Crohn's Disease.

Journal: Cells

Published: June 15, 2022

Phase 1 and preclinical profiling of ESM-HDAC391, a myeloid-targeted histone deacetylase inhibitor, shows enhanced pharmacology and monocytopaenia.

Phase 1 and preclinical profiling of ESM-HDAC391, a myeloid-targeted histone deacetylase inhibitor, shows enhanced pharmacology and monocytopaenia.

Journal: British journal of clinical pharmacology

Published: January 17, 2022

Combined noncanonical NF-κB agonism and targeted BET bromodomain inhibition reverse HIV latency ex vivo.

Combined noncanonical NF-κB agonism and targeted BET bromodomain inhibition reverse HIV latency ex vivo.

Journal: The Journal of clinical investigation

Published: December 07, 2021

Carboxylesterase-1 Assisted Targeting of HDAC Inhibitors to Mononuclear Myeloid Cells in Inflammatory Bowel Disease.

Carboxylesterase-1 Assisted Targeting of HDAC Inhibitors to Mononuclear Myeloid Cells in Inflammatory Bowel Disease.

Journal: Journal of Crohn's & colitis

Published: October 11, 2021

A Qualified Success: Discovery of a New Series of ATAD2 Bromodomain Inhibitors with a Novel Binding Mode Using High-Throughput Screening and Hit Qualification.

A Qualified Success: Discovery of a New Series of ATAD2 Bromodomain Inhibitors with a Novel Binding Mode Using High-Throughput Screening and Hit Qualification.

Journal: Journal of medicinal chemistry

Published: August 10, 2019

Targeting Histone Deacetylases in Myeloid Cells Inhibits Their Maturation and Inflammatory Function With Limited Effects on Atherosclerosis.

Targeting Histone Deacetylases in Myeloid Cells Inhibits Their Maturation and Inflammatory Function With Limited Effects on Atherosclerosis.

Journal: Frontiers in pharmacology

Published: June 26, 2019

Bromodomain inhibitor I-BET151 suppresses immune responses during fungal-immune interaction.

Bromodomain inhibitor I-BET151 suppresses immune responses during fungal-immune interaction.

Journal: European journal of immunology

Published: January 04, 2019

Aiming to Miss a Moving Target: Bromo and Extra Terminal Domain (BET) Selectivity in Constrained ATAD2 Inhibitors.

Aiming to Miss a Moving Target: Bromo and Extra Terminal Domain (BET) Selectivity in Constrained ATAD2 Inhibitors.

Journal: Journal of medicinal chemistry

Published: September 19, 2018

Inhibition of BET Proteins Reduces Right Ventricle Hypertrophy and Pulmonary Hypertension Resulting from Combined Hypoxia and Pulmonary Inflammation.

Inhibition of BET Proteins Reduces Right Ventricle Hypertrophy and Pulmonary Hypertension Resulting from Combined Hypoxia and Pulmonary Inflammation.

Journal: International journal of molecular sciences

Published: July 05, 2018

BET bromodomain inhibitors show anti-papillomavirus activity in vitro and block CRPV wart growth in vivo.

BET bromodomain inhibitors show anti-papillomavirus activity in vitro and block CRPV wart growth in vivo.

Journal: Antiviral research

Published: September 25, 2017

Muscle hypertrophy in hypoxia with inflammation is controlled by bromodomain and extra-terminal domain proteins.

Muscle hypertrophy in hypoxia with inflammation is controlled by bromodomain and extra-terminal domain proteins.

Journal: Scientific reports

Published: May 23, 2017

Showing 1-12 of 16

Last Updated: 09/26/2026